Discourage Using the New Oral Antiplatelet Drug Zontivity Alone

You'll hear controversy about the new oral antiplatelet drug, Zontivity (zon-TIV-i-tee, vorapaxar).

It's the first protease-activated receptor-1 (PAR-1) antagonist...and inhibits platelet aggregation for about 4 weeks.

It's approved for use with low-dose aspirin and/or clopidogrel after a heart attack or in patients with peripheral artery disease...to further reduce CV events or death.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote